Zacks Research Weighs in on AbbVie's Q2 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV - Free Report) - Stock analysts at Zacks Research reduced their Q2 2025 EPS estimates for AbbVie in a research note issued on Tuesday, July 22nd. Zacks Research analyst S. Ganoria now anticipates that the company will post earnings per share of $2.87 for the quarter, down from their previous forecast of $3.27. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share. Zacks Research also issued estimates for AbbVie's FY2025 earnings at $11.81 EPS.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald began coverage on shares of AbbVie in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price objective for the company. BNP Paribas raised shares of AbbVie to a "hold" rating in a research note on Thursday, May 8th. Morgan Stanley boosted their target price on shares of AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a report on Monday, April 28th. Wall Street Zen downgraded shares of AbbVie from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Finally, Bank of America increased their price target on shares of AbbVie to $204.00 and gave the stock a "hold" rating in a report on Monday, June 9th. Eight equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, AbbVie presently has an average rating of "Moderate Buy" and an average target price of $211.29.

AbbVie Price Performance

ABBV traded down $0.61 during trading hours on Friday, hitting $190.22. The company's stock had a trading volume of 3,786,155 shares, compared to its average volume of 6,461,288. The business's 50-day moving average price is $187.62 and its 200-day moving average price is $189.70. AbbVie has a 12 month low of $163.81 and a 12 month high of $218.66. The stock has a market cap of $336.00 billion, a price-to-earnings ratio of 80.94, a P/E/G ratio of 1.27 and a beta of 0.48. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.31% and a return on equity of 412.03%. The firm had revenue of $13.34 billion for the quarter, compared to analysts' expectations of $12.91 billion. During the same quarter last year, the business posted $2.31 earnings per share. The company's revenue for the quarter was up 8.4% compared to the same quarter last year.

Institutional Trading of AbbVie

Hedge funds and other institutional investors have recently modified their holdings of the stock. TD Capital Management LLC grew its position in AbbVie by 82.9% in the 1st quarter. TD Capital Management LLC now owns 128 shares of the company's stock valued at $27,000 after acquiring an additional 58 shares in the last quarter. Marshall & Sullivan Inc. WA purchased a new stake in AbbVie in the second quarter valued at approximately $25,000. Abound Financial LLC purchased a new stake in AbbVie in the first quarter valued at approximately $30,000. EnRich Financial Partners LLC increased its holdings in shares of AbbVie by 196.4% in the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after purchasing an additional 110 shares during the period. Finally, Cypress Capital Management LLC WY acquired a new position in shares of AbbVie in the first quarter valued at approximately $35,000. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a $1.64 dividend. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date is Tuesday, July 15th. AbbVie's dividend payout ratio (DPR) is presently 279.15%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.